Formosa Laboratories today announced that its Eribulin Injection has received approval from the U.S. Food and Drug Administration (US FDA) under the Abbreviated New Drug Application (ANDA) pathway (approval details: https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=219054#68). This marks the first ANDA approval for Formosa Laboratories and represents a significant corporate milestone.
This approval not only demonstrates the Company’s capabilities in API, FDF development as well as regulatory execution, but also signifies Formosa Laboratories’ official entry into the U.S. finished dosage market, further strengthening its global presence. The product launch will help expand treatment options and address clinical needs for patients.
Formosa Laboratories remains committed to a patient-centric approach and will continue to deliver high-quality and affordable medicines, fulfilling its long-term dedication to patient care.
This approval not only demonstrates the Company’s capabilities in API, FDF development as well as regulatory execution, but also signifies Formosa Laboratories’ official entry into the U.S. finished dosage market, further strengthening its global presence. The product launch will help expand treatment options and address clinical needs for patients.
Formosa Laboratories remains committed to a patient-centric approach and will continue to deliver high-quality and affordable medicines, fulfilling its long-term dedication to patient care.